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Delaying progression of disability is a key therapeutic 
goal of disease-modifying therapy (DMT) in patients 
with multiple sclerosis (MS).1,2 Multiple outcome 
measures have been developed to assess disease pro-
gression or patient function in clinical studies of 
patients with MS. The Expanded Disability Status 
Scale (EDSS) is the most established outcome meas-
ure in MS clinical trials.3,4 The EDSS has notable 
limitations, particularly with regard to insensitivity in 
upper extremity function and non-motor functions 
once ambulation is severely restricted.2,5–7 Additionally, 
it does not provide an adequate assessment of cogni-
tive impairment related to MS.6
The Multiple Sclerosis Functional Composite 
(MSFC), developed to overcome some of the limita-
tions of the EDSS, comprises three components that 
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Abstract
Background: Demonstration of clinical benefits on disability progression measures is an important attri-
bute of effective multiple sclerosis (MS) treatments.
Objective: Examine efficacy of daclizumab beta versus intramuscular (IM) interferon beta-1a on mea-
sures of disability progression in patient subgroups from DECIDE.
Methods: Twenty-four-week confirmed disability progression (CDP), 24-week sustained worsening on 
a modified Multiple Sclerosis Functional Composite (MSFCS) where 3-Second Paced Auditory Serial 
Addition Test was replaced by Symbol Digit Modalities Test, and proportion of patients with clinically 
meaningful worsening in 29-Item Multiple Sclerosis Impact Scale physical impact subscale (MSIS-29 
PHYS) score from baseline to week 96 were examined in the overall population and subgroups defined 
by baseline demographic/disease characteristics.
Results: Daclizumab beta significantly reduced risk of 24-week CDP (hazard ratio (HR), 0.73; 95% con-
fidence interval (95% CI), 0.55–0.98), risk of 24-week sustained MSFCS progression (HR, 0.80; 95% CI, 
0.67–0.95), and odds of clinically meaningful worsening in MSIS-29 PHYS (odds ratio, 0.76; 95% CI, 
0.60–0.95) versus IM interferon beta-1a. Point estimates showed trends favoring daclizumab beta over IM 
interferon beta-1a across several patient subgroups for all three outcome measures.
Conclusion: Daclizumab beta showed consistent benefit versus IM interferon beta-1a across measures 
assessing patient disability/function and across a range of clinical baseline characteristics in patients with 
relapsing-remitting MS.
Keywords: Daclizumab beta, disability progression, efficacy, interferon beta-1a, relapsing-remitting 
multiple sclerosis, subgroup analysis
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evaluate different patient functional outcomes: the 
Timed 25-Foot Walk (T25FW) for ambulation, the 
9-Hole Peg Test (9HPT) for hand/arm dexterity, and 
the 3-Second Paced Auditory Serial Addition Test 
(PASAT-3) for cognition.7 Because clinical interpreta-
tion of the composite z-score methodology employed 
for the MSFC can be challenging, examining worsen-
ing of each MSFC component separately has been 
proposed as an alternative analytic measure.8 It has 
also been suggested that the MSFC is a more robust 
assessment if the Symbol Digit Modalities Test 
(SDMT) is used instead of the PASAT-3 for assessing 
cognition.6,9 The SDMT is easier and faster to admin-
ister,10 may be more reliable,6,9,11 and has demon-
strated smaller practice effects,9 a known concern 
with the PASAT-3.12
DECIDE (NCT01064401) was a phase 3 study that 
evaluated the efficacy and safety of treatment with 
daclizumab beta 150 mg subcutaneous once every 
4 weeks versus interferon (IFN) beta-1a 30 mcg intra-
muscular (IM) once weekly in patients with relaps-
ing-remitting MS (RRMS).13 Daclizumab beta 
(formerly known as daclizumab high-yield process) 
was approved as ZINBRYTA®, which has a different 
form and structure than an earlier form of daclizumab. 
In the overall study population, daclizumab beta dem-
onstrated greater benefit compared with IM IFN beta-
1a on several outcome measures of disability. While 
12-week confirmed disability progression (CDP) as 
assessed by EDSS did not differ significantly between 
the two treatment groups, 24-week CDP, a more 
robust outcome than 12-week CDP, was reduced by 
27% in patients treated with daclizumab beta versus 
IM IFN beta-1a (p = 0.033).13 At week 96, patients in 
the daclizumab beta versus the IM IFN beta-1a group 
had greater median change from baseline (25th, 75th 
percentiles) in overall MSFC score (0.091 (−0.096 to 
0.287) vs 0.055 (−0.136 to 0.240), respectively; 
p < 0.001), in each individual MSFC component score 
(all p < 0.05), and a greater mean change on the SDMT 
(p = 0.03).13 Additionally, patients in the daclizumab 
beta group had a 24% reduction in the odds of experi-
encing a clinically meaningful worsening in the 
patient-reported 29-Item Multiple Sclerosis Impact 
Scale physical impact subscale (MSIS-29 PHYS) 
score at week 96 (odds ratio (OR), 0.76; 95% confi-
dence interval (95% CI), 0.60–0.95; nominal 
p = 0.0176).14
In addition to demonstrating efficacy of an MS ther-
apy in the overall study population, subgroup analy-
ses may inform on treatment effects across different 
demographic and clinical characteristics.15,16 This 
post hoc analysis examined treatment effects of 
daclizumab beta compared with IM IFN beta-1a on 
measures of patient disability or impairment across 
patient subgroups according to baseline demographic 
and disease characteristics in DECIDE. The measures 
included a modified MSFC, in which the PASAT-3 
was replaced with the SDMT.
Methods
Full details of DECIDE have been reported.13 Briefly, 
patients of age 18–55 years with a confirmed diagnosis 
of RRMS were randomized (1:1) to daclizumab beta 
150 mg subcutaneous every 4 weeks and IM placebo 
once weekly or IFN beta-1a 30 mcg IM once weekly 
and subcutaneous placebo every 4 weeks for a mini-
mum of 96 weeks and up to 144 weeks. Magnetic reso-
nance imaging (MRI) consistent with MS, baseline 
EDSS score of 0–5.0, and two or more relapses within 
the previous 3 years (one or more in year before study) 
or one or more relapse(s) and one or more new MRI 
lesion(s) within 2 years (one or more event(s) in year 
before study) constituted additional inclusion criteria. 
All patients provided written informed consent. 
Central and local ethics committee approvals were 
obtained, and the study was performed in accordance 
with the Declaration of Helsinki and the International 
Conference on Harmonisation Guidelines for Good 
Clinical Practice.17
Assessments
Three outcome measures of patient disability/function 
were examined for the overall study population and by 
subgroup. These included 24-week CDP as measured 
by EDSS18 (tertiary endpoint in DECIDE), 24-week 
sustained worsening on the MSFCS (analysis per-
formed post hoc), and the proportion of patients expe-
riencing a clinically meaningful worsening in MSIS-29 
PHYS score at week 96 (secondary endpoint in 
DECIDE). Twenty-four-week CDP was defined as an 
increase in the EDSS score of ⩾1.0 point(s) from a 
baseline score of ⩾1.0 or ⩾1.5 points from a baseline 
score of 0 confirmed after 24 weeks.13 Twenty-four-
week sustained worsening on the MSFCS, based in 
part on an analysis by Rudick et al.,8 was defined as 
⩾20% worsening in T25FW score, ⩾20% worsening 
in 9HPT score (mean of both hands), or a decrease of 
⩾4 points in SDMT score (clinically meaningful 
change)19 sustained for 24 weeks. Additional analyses 
were run using alternative methods for evaluating 
9HPT. These included examining a 20% worsening in 
9HPT score for the dominant hand only or for either 
the dominant hand or the non-dominant hand. Finally, 
in order to capture clinically meaningful changes due 
to MS from the patents’ perspective, worsening from 
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baseline in MSIS-29 PHYS score was analyzed at 
week 96. An increase from baseline on the MSIS-29 of 
⩾7.5 points has been shown to indicate clinically 
meaningful worsening in a large clinical study 
population.20
EDSS, T25FW, and 9HPT scores were assessed at 
baseline and every 12 weeks until week 144 (or end of 
study). SDMT (oral response format) and MSIS-29 
(version 1) scores were assessed at baseline and every 
24 weeks until week 144 or end of study.
Subgroups based on baseline demographics were age 
(⩽35, >35 years) and sex (female, male). Subgroups 
based on baseline disease characteristics were disabil-
ity as defined by EDSS score (<3.5, ⩾3.5), relapses in 
previous 12 months (one or less, two or more), disease 
duration (<3, ⩾3 to <10, or ⩾10 years), gadolinium-
enhancing (Gd+) lesions (absent, present), T2 hyper-
intense lesion volume (<, ⩾ median), disease activity 
(highly active, less active; highly active was defined 
as two or more relapses in the year before randomiza-
tion and one or more Gd+ lesion(s) on baseline MRI, 
less active otherwise), prior DMT use (yes, no; 
excluding steroids but including any prior disease-
modifying or immunomodulatory therapy for MS, 
such as alemtuzumab, azathioprine, cladribine, cyclo-
phosphamide, fingolimod, fumaric acid, glatiramer 
acetate, immune globulin, IFN beta-1a, IFN beta-1b, 
laquinimod, methotrexate, mitoxantrone, mycophe-
nolic acid, natalizumab, teriflunomide, or temsiroli-
mus), and prior IFN beta use (yes, no; including IFN 
beta, IFN beta-1a, and IFN beta-1b).
Statistical analyses
All analyses were performed on the intention-to-treat 
population (randomized patients who received one or 
more dose(s) of study drug) with non-missing baseline 
assessments.13 p-values reported were not adjusted for 
multiple testing. Disability progression based on 
EDSS score was analyzed by a Cox proportional haz-
ards model adjusted for baseline EDSS score (continu-
ous variable), prior IFN beta use (yes, no), and baseline 
age (⩽35, >35 years), excluding covariates defining 
the subgroup. Among patients with one or more tenta-
tive progression event(s), a logistic model was used to 
estimate the probability of confirmation for patients 
with a missing EDSS assessment to confirm progres-
sion. The logistic model adjusted for treatment group, 
EDSS score at baseline (continuous variable), change 
in EDSS score from baseline to the time of tentative 
progression, and presence or absence of a relapse 
within the last 29 days of the tentative progression.13 
For patients with multiple tentative progressions, the 
confirmed (if patient had a confirmed progression) or 
the last (if patient did not have any tentative progres-
sions confirmed) tentative progression record was 
retained. In total, 50 imputed datasets were generated 
using the estimated probabilities from this logistic 
regression model. The Cox proportional hazards 
model was conducted on subgroups of each of the 50 
datasets. Rubin’s rule21 was used to combine the HR, 
standard error of this estimate, and p-values.
MSFCS progression was analyzed by Cox propor-
tional hazards model adjusted for prior IFN beta use 
(yes, no) and baseline age (⩽35, >35 years), exclud-
ing covariates defining the subgroup. Patients with a 
tentative progression at the end of treatment period 
visit and no confirmation assessment were censored 
at their last assessment. Data were re-censored at 
2 years, that is, 96 weeks. Missing T25FW and 9HPT 
data were imputed using the method described in the 
supplemental material of Kappos et al.13 Missing 
SDMT values in post-baseline visits were imputed 
using last observation carried forward. For patients 
with missing SDMT values, the other endpoints were 
used to derive time to first sustained progression.
Analyses of patients with a clinically meaningful wors-
ening in MSIS-29 PHYS score were based on logistic 
regression models, adjusted for baseline MSIS-29 PHYS 
score, baseline Beck Depression Inventory-II score, 
prior IFN beta use, and baseline age (⩽35, >35 years), 
but excluded covariates defining the subgroup. If a 
patient was missing data for <10 of the 20 items that 
make up the PHYS score, then the mean of the non-
missing items was used for the missing items. If the 
patient was missing ⩾10 of the 20 items that make up 
the PHYS score, or missing the questionnaire entirely, or 
if the questionnaire was completed after the patient 
switched to alternative MS medication, a random effects 
model was used to estimate MSIS-29 PHYS score.
Results
The intention-to-treat population of DECIDE included 
1841 patients; 922 were randomized to IM IFN beta-
1a and 919 were randomized to daclizumab beta.13 
Details of the demographics and baseline characteris-
tics of the DECIDE study population are published.13 
Relevant demographics and baseline characteristics 
are shown in Table 1.
Twenty-four-week CDP
Across all subgroups, point estimates of the risk of 
24-week CDP showed consistent trends favoring 
daclizumab beta over IM IFN beta-1a (Figure 1) and 
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supported the results observed for 24-week CDP in 
the overall study population.13 For this outcome 
measure, minor variations in treatment effect esti-
mates were observed and there was no convincing 
evidence of effect modification. HRs ranged from 
0.46 to 0.87, where the greatest risk reduction was 
observed in patients ⩽35 years of age.
Twenty-four-week sustained MSFCS progression
Fewer daclizumab beta (24% (224/919)) versus IM IFN 
beta-1a patients (28% (259/922)) met the criteria for 
24-week sustained MSFCS progression at week 96. Of 
patients who progressed, MSFCS progression was most 
commonly driven by SDMT (IM IFN beta-1a, 56% 
(146/259); daclizumab beta, 55% (124/224)), followed 
by T25FW (IM IFN beta-1a, 34% (89/259); daclizumab 
beta, 33% (75/224)) and 9HPT scores (IM IFN beta-1a, 
6% (16/259); daclizumab beta, 8% (17/224)). The rest of 
the patients progressed on two or more components at 
the same time. In the overall study population, treatment 
with daclizumab beta resulted in a 20% reduction (HR, 
0.80; 95% CI, 0.67–0.95; p = 0.0132) in risk of 24-week 
sustained MSFCS progression compared with IM IFN 
beta-1a. Point estimates of risk of 24-week sustained 
progression of the MSFCS show consistent trends favor-
ing daclizumab beta over IM IFN beta-1a across all sub-
groups. HRs ranged from 0.56 to 0.92. While there were 
minor variations in treatment effect estimates, there was 
no convincing evidence of effect modification (Figure 
2). Nominal statistical significance of risk reduction was 
noted for age ⩽ 35 years, baseline EDSS score ⩾3.5, two 
or more relapses in the previous year, presence of base-
line Gd+ lesions, T2 hyperintense lesion volume 
⩾median, less active disease activity at baseline, no 
prior DMT use, no prior IFN beta use, and time since 
diagnosis ⩾10 years. Similar results were observed 
when alternative methods were used for assessing 9HPT 
score (both dominant and non-dominant hands included, 
dominant hand only; Figure S1).
Clinically meaningful worsening in MSIS-29 
PHYS score
Treatment with daclizumab beta resulted in a 24% 
reduction in the odds of a clinically meaningful wors-
ening in MSIS-29 PHYS score at week 96 versus IM 
IFN beta-1a (OR, 0.76; 95% CI, 0.60–0.95; 
p = 0.0176).13 ORs of the risk of clinically meaning-
ful worsening in MSIS-29 PHYS score at week 96 
Table 1. Patient demographics and baseline disease characteristics in DECIDE.
Characteristic IM IFN beta-1a (n = 922) Daclizumab beta (n = 919)
Age, years, mean (SD) 36.2 (9.3) 36.4 (9.4)
Female, n (%) 627 (68) 625 (68)
White, n (%) 828 (90) 823 (90)
Time since MS diagnosis, years, mean (median) 4.1 (2.0) 4.2 (2.0)
Number of relapses in previous year, mean (SD) 1.6 (0.8) 1.5 (0.7)
Number of relapses in previous 3 years,a mean (SD) 2.7 (1.3) 2.7 (1.2)
Baseline EDSS score
 Mean (SD) 2.5 (1.3) 2.5 (1.2)
 Median (range) 2.3 (0−6.0) 2.0 (0−5.5)
SDMT score,b mean (SD) 47.7 (16.1) 48.5 (15.9)
MSIS-29 PHYS score,c mean (SD) 21.9 (19.2) 21.5 (19.8)
MSIS-29 PSYCH score,d mean (SD) 28.6 (21.1) 28.8 (21.8)
MSFC score,e median (25th, 75th percentiles) 0.118 (−0.377, 0.482) 0.139 (−0.335, 0.491)
 T25FW z-score 0.223 (−0.042, 0.372) 0.223 (−0.034, 0.372)
 9HPT z-score 0.035 (−0.622, 0.633) 0.065 (−0.597, 0.661)
 PASAT-3 z-scorec 0.264 (−0.619, 0.794) 0.352 (−0.531, 0.794)
IM: intramuscular; IFN: interferon; SD: standard deviation; MS: multiple sclerosis; EDSS: Expanded Disability Status Scale; SDMT: 
Symbol Digit Modalities Test; MSIS-29: 29-Item Multiple Sclerosis Impact Scale; PHYS: physical impact subscale; PSYCH: 
psychological impact subscale; MSFC: multiple sclerosis functional composite; T25FW: Timed 25-Foot Walk; 9HPT: 9-Hole Peg 
Test; PASAT-3: 3-Second Paced Auditory Serial Addition Test.
aDaclizumab beta, n = 918.
bIM IFN beta-1a, n = 880; daclizumab beta, n = 884.
cIM IFN beta-1a, n = 912; daclizumab beta, n = 906.
dIM IFN beta-1a, n = 912; daclizumab beta, n = 904.
eIM IFN beta-1a, n = 920; daclizumab beta, n = 916.
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show trends favoring daclizumab beta over IM IFN 
beta-1a across all subgroups (Figure 3). ORs ranged 
from 0.57 to 0.97. Nominal statistical significance of 
risk reduction was noted for female sex, 
age ⩽ 35 years, disease duration <3 years, baseline 
EDSS score <3.5, two or more relapses in previous 
year, presence of baseline Gd+ lesions, T2 hyperin-
tense lesion volume ⩾median, no prior DMT use, 
and no prior IFN beta use.
Discussion
In the overall study population of DECIDE, treatment 
with daclizumab beta resulted in significant reductions 
in risk of 24-week CDP as measured using the EDSS, 
and risk of 24-week sustained progression on the 
MSFCS, a version of the MSFC replacing the PASAT-3 
with the SDMT. Additionally, patients receiving dacli-
zumab beta had reduced risk of experiencing a clini-
cally meaningful worsening in MSIS-29 PHYS score 
compared with IM IFN beta-1a. Daclizumab beta 
treatment also showed consistent benefit versus IM 
IFN beta-1a across multiple patient subgroups, thus 
supporting the treatment effect seen in the overall pop-
ulation for each of the outcome measures examined 
independent of baseline characteristics. Treatment 
effect did not reach statistical significance for all sub-
groups for any of the three outcome measures, how-
ever, age ⩽ 35 years and baseline T2 hyperintense 
lesion volume ⩾median reached nominal significance 
for all three measures.
In this study, daclizumab beta demonstrated greater 
efficacy versus IM IFN beta-1a on two distinct meas-
ures of disability progression, 24-week CDP as meas-
ured by EDSS and the MSFCS. Despite its wide use, 
the EDSS has been criticized for a lack of sensitivity 
to change and inadequate assessment of cognition.5,22 
The MSFC was developed to address these limita-
tions and provide information supplemental to that 
provided by the EDSS.7 Both a 15% and a 20% wors-
ening from baseline in at least one MSFC component 
(sustained for 3 months) were found to be sensitive 
measures of disability progression.8
Figure 1. Forest plot for 24-week confirmed disability progression for daclizumab beta versus IM IFN beta-1a by 
baseline demographics and disease characteristics.
CI: confidence interval; EDSS: Expanded Disability Status Scale; Gd+: gadolinium-enhancing; IFN: interferon; IM: intramuscular; MS: 
multiple sclerosis; SC: subcutaneous.
aMissing baseline Gd+ lesions data: IM IFN beta-1a, n = 13; daclizumab beta, n = 19.
bMissing baseline T2 hyperintense lesion volume data: IM IFN beta-1a, n = 14; daclizumab beta, n = 19.
cMissing baseline disease activity data: IM IFN beta-1a, n = 5; daclizumab beta, n = 12.
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This study examined MSFCS progression sustained 
for 6 months, which is considered more robust than 
the 3-month interval and is recommended by the 
European Medicines Agency when examining 
CDP.2,23 This study also explored three methodologies 
for the 9HPT component of the MSFCS: mean of both 
hands, dominant hand only, and either the dominant 
or non-dominant hand. The results of this MSFCS 
analysis did not appear to be impacted by choice of 
methodology.
Rudick et al. reported that, of patients who pro-
gressed on the MSFCS using a 20% worsening, the 
majority of patients progressed first on the T25FW 
(51% of placebo and 54% of natalizumab), while 
few patients progressed first on the PASAT-3 (5% of 
placebo and 6% of natalizumab).8 In contrast, the 
present analysis found that the majority of the 
patients with MSFCS progression worsened first on 
the SDMT, suggesting that the SDMT has poten-
tially greater sensitivity compared with the PASAT-3 
in detecting cognitive decline.
In contrast to the EDSS and MSFC, which are clinical 
assessment measures administered by physicians or 
trained professionals, the patient-reported MSIS-29 
was developed as a disease-specific tool meant to 
capture the impact of MS from the perspective of the 
patient.24 Point estimates from the subgroup analyses 
of the proportion of patients with clinically meaning-
ful worsening in the MSIS-29 PHYS consistently 
favored daclizumab beta versus IM IFN beta-1a.
These analyses should be interpreted as exploratory 
and hypothesis generating for future studies. Some 
subgroups had small sample sizes, which resulted in 
wider CIs for these subgroups.15 Additionally, no 
adjustments were made for multiple testing. Inherent 
differences in the properties of the tools (e.g. clinician-
administered vs patient-reported) and the different 
functions assessed by each also may contribute to the 
differences observed across them.25
Overall, the results of these post hoc subgroup analyses 
of outcome measures assessing disability progression, 
Figure 2. Forest plot for 24-week sustained modified Multiple Sclerosis Functional Composite progression for 
daclizumab beta versus IM IFN beta-1a by baseline demographics and disease characteristics.
CI: confidence interval; EDSS: Expanded Disability Status Scale; Gd+: gadolinium-enhancing; IFN: interferon; IM: intramuscular; MS: 
multiple sclerosis; SC: subcutaneous.
aMissing baseline Gd+ lesions data: IM IFN beta-1a, n = 13; daclizumab beta, n = 19.
bMissing baseline T2 hyperintense lesion volume data: IM IFN beta-1a, n = 14; daclizumab beta, n = 19.
cMissing baseline disease activity data: IM IFN beta-1a, n = 5; daclizumab beta, n = 12.
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as well as patient-reported function, indicate that the 
efficacy of daclizumab beta treatment compared with 
IM IFN beta-1a was superior and consistent across a 
range of baseline demographic and disease characteris-
tics in patients with RRMS in DECIDE.
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